Pioneering Stem Cell/Gene Therapy Trials

Roger Bertolotti, CNRS, Molecular Genetics, Department of Hepato-Gastroenterology, Faculty of Medicine, University of Nice-Sophia Antipolis, France. Keiyo Ozawa, Division of Hematology, Department of Medicine, and Division of Cell Transplantation and Transfusion, and Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Japan. H. Kirk Hammond, Division of Cardiology, VA San Diego Healthcare System and University of California, San Diego School of Medicine, San Diego, California.

• Introduction; Stem cell-gene therapy: a breakthrough combination magnified by therapeutic stem cell homing; Inherited disease: stem cells and life-long therapeutic gene expression paradigm; Clinical gene therapy trials for ADA deficiency and other Immunodeficiencies; Regenerative cardiovascular medicine: transient gene therapy and autologous stem cell transplantation 1. Transient angiogenic/vasculogenic gene therapy clinical trials Vascular endothelial growth factor (VEGF) gene therapy for critical limb ischemia 2. Autologous stem cell therapy: clinical trials for cardiovascular Disease 3. Synergyzing stem cell* and gene-therapy for cardiovascular Regeneration; Neurodegenerative disease: long-term gene therapy and neural/stem cell targets; Non-invasive monitoring of clinical gene therapy trials